Immunovant, Inc. (IMVT): Cash & Equivalents
$902.11M
As of 2026-03-31
$797.80M
As of 2026-06-30
+33.8%
3-year compound annual growth
+17.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $902.11M | +26.4% | 2026-05-20, Balance as of period end |
| 2025-03-31 | $713.97M | +12.4% | 2026-05-20, Balance as of period end |
| 2024-03-31 | $635.37M | +68.7% | 2025-05-29, Balance as of period end |
| 2023-03-31 | $376.53M | -23.8% | 2024-05-29, Balance as of period end |
| 2022-03-31 | $493.82M | +23.4% | 2023-05-22, Balance as of period end |
| 2021-03-31 | $400.15M | +297.9% | 2022-06-08, Balance as of period end |
| 2020-03-31 | $100.57M | n/m | 2021-06-01, Balance as of period end |
| 2019-03-31 | $6.99M | n/a | 2020-06-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Immunovant, Inc. (IMVT) | 2026-03-31 | $902.11M | +26.4% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $232.19M | +4.1% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $163.08M | +41.0% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $467.71M | +2.6% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $167.20M | -70.2% |
| Denali Therapeutics Inc. (DNLI) | 2025-12-31 | $205.33M | +17.4% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $32.49M | -87.4% |
| Novavax Inc (NVAX) | 2025-12-31 | $240.63M | -54.6% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $496.30M | +43.9% |
Compare IMVT, VIR, IOVA, IMCR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗